Acute severe asthma in a patient demanding Vamana: timing and contraindications
A 34-year-old shopkeeper with a 12-year history of bronchial asthma is brought during a monsoon exacerbation with breathlessness at rest, cough productive of thick white sputum, and inability to lie flat. He uses budesonide–formoterol 200/6 twice daily and salbutamol as needed, but has used salbutamol six times today. Examination: RR 28/min, pulse 112/min, SpO2 91% on room air, bilateral expiratory wheeze, accessory muscle use, PEFR 45% of predicted, temperature 37.4 °C. He ate a heavy meal two hours ago and feels nauseated. He has a healed duodenal ulcer on endoscopy from two years ago and takes occasional NSAIDs for knee pain. He is a smoker and has never taken oral steroids. He has heard that 'Vamana cures asthma permanently' and demands it today.
1. Is he a candidate for Vamana today? Justify your answer on the basis of his clinical state and the classical contraindications.
Read the worked answer
No. This is an acute severe exacerbation: SpO2 91% on room air, RR 28, PEFR 45% of predicted, accessory muscle use and inability to lie flat. Vamana requires a stable patient with adequate bala, a nirama koshta, an empty stomach and no acute distress. It raises intrathoracic and intra-abdominal pressure, provokes coughing and vagal stimulation, and carries an aspiration risk in a dyspnoeic, nauseated patient - it can precipitate bronchospasm rather than relieve it.
Classical contraindications that apply here include recent food intake (bhukta), nausea, severe/acute shwasa with exhaustion, and peptic ulcer disease with a bleeding risk. A healed duodenal ulcer still makes violent straining and repeated retching undesirable, especially with NSAID exposure.
He must also be told clearly that Vamana is not a permanent cure. It is a shodhana procedure for kapha-dominant tamaka shwasa, capable of prolonged symptom control when done in the stable phase after proper purvakarma, not an emergency treatment. Consent should be for stabilisation now and a planned shodhana later.
2. Outline your management for the next 72 hours, including what you will do about his demand for Panchakarma.
Read the worked answer
Immediate: oxygen titrated to SpO2 ≥ 94%; nebulised salbutamol with ipratropium; systemic corticosteroid (prednisolone 40–50 mg or parenteral hydrocortisone); continue ICS-formoterol; consider intravenous magnesium sulphate if the response is poor. Monitor RR, pulse, SpO2 and PEFR serially. Arrange admission - SpO2 below 92% and PEFR below 50% are severe features, and a patient who has needed six reliever doses in a day is not safe for outpatient-only care.
Avoid: sedatives, NSAIDs for the knee during this period, and any dhumapana or vamana while he is distressed.
Explain and document: tell him and a relative that Ayurvedic shodhana will be planned after the acute phase, with a written timeline. This converts the demand into an informed plan rather than a refusal.
Ayurvedic support once nausea settles: Sitopaladi churna with honey, Yashtimadhu churna, and Vasa swarasa in divided doses, with a light warm diet. Reassess at 24 and 72 hours; document PEFR trend before discharge and set up an action plan for future exacerbations.
3. Once stable, which Ayurvedic formulations and Panchakarma procedures would you select, and which would you avoid because of the ulcer history?
Read the worked answer
Select: after deepana-pachana, Snehapana with Vasa ghrita or Kantakari ghrita, then Vamana with Madanaphala and Yashtimadhu/Vacha under monitoring, followed by dhumapana with Vasa or Manahshila preparations after meals and anuvasana with Vasa taila. Virechana with Triphala or Eranda is reasonable if constipation is prominent. Formulations: Sitopaladi, Talisadi, Shringyadi churna, Pushkaramula, Bharangi, Kantakari and Shirisha.
Avoid or modify: Kanakasava and other alcohol-based asavas, because alcohol aggravates dyspepsia and ulcer risk; large-dose Pippali; unidentified herbo-mineral rasa preparations with mercury or arsenic in a patient with a ulcer history and no monitoring capacity; strong irritant dhumapana during any exacerbation; and any NSAID. Basti is acceptable once stable but should not be used as a substitute for inhaled corticosteroid control, which must continue.
Document a written self-management plan with reliever use thresholds, and review the ulcer history before every shodhana cycle.